Sort
35,931 grants matching “parkinsons”
Omics Analyses of HIV and Substance Use Disorder
$856,189Vez Repunte-Canonigo · Scripps Research Institute, The · R01 · FY2021 · DA
In Vitro and In Vivo Characterization of Alpha-Synuclein PET Radiotracers
$856,001Robert H Mach · University Of Pennsylvania · U19 · FY2022 · NS
Study of protein folding and misfolding by NMR spectroscopy
$855,890Adriaan Bax · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK
The neural bases of placebo effects and their relation to regulatory processes
$855,877Tor Dessart Wager · Dartmouth College · R37 · FY2024 · MH
Understanding Alzheimer's Disease in the Context of the Aging Brain
$855,775Ana M. Cuervo · Albert Einstein College Of Medicine, Inc · RF1 · FY2016 · AG
Alpha Synuclein, cellular dysfunction and Parkinson disease
$855,755Mark Cookson · National Institute On Aging · ZIA · FY2024 · AG
In Vitro and In Vivo Characterization of Alpha-Synuclein PET Radiotracers
$855,716Robert H Mach · University Of Pennsylvania · U19 · FY2023 · NS
Natural Language Processing and Automated Speech Recognition to Identify Older Adults with Cognitive Impairment
$855,710Alex D. Federman · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · AG
Omics Analyses of HIV and Substance Use Disorder
$855,649Vez Repunte-Canonigo · Scripps Research Institute, The · R01 · FY2019 · DA
Discovery of probes that enhance expression of the neuroprotective protein Klotho
$855,556Carmela R Abraham · Boston University Medical Campus · R56 · FY2016 · AG
Corticostriatal mechanisms of action learning and habit formation
$855,230Rui Manuel Costa · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2009 · AA
Levodopa Pharmacokinetic Optimization by Metal Coordination
$855,191Thomas Piccariello · Synthonics, Inc. · R44 · FY2013 · NS
MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
$854,804Mayo Clinic · R01 · FY2004 · ES
Development of the RXR agonist IRX4204 to treat Multiple Sclerosis and other Immune related Diseases
$854,395Rosh Chandraratna · Io Therapeutics, Inc. · R44 · FY2016 · AI
Omics Analyses of HIV and Substance Use Disorder
$854,351Vez Repunte-Canonigo · Scripps Research Institute, The · R01 · FY2022 · DA
Fluorescent IRE Sensor for Synucleinopathy Drug Discovery
$853,817Wen Shen · Lucerna, Inc. · R44 · FY2022 · NS
Design And Development Of Experimental Therapeutics
$853,810Nigel H. Greig · National Institute On Aging · ZIA · FY2020 · AG
Mechanisms of Parkinson Disease and Related Disorders
$852,963David Goldstein · National Institute Of Neurological Disorders And Stroke · ZIA · FY2016 · NS
Tele-Health Extension for Phase 3 Parkinson's Disease Trial Cohorts
$852,847Michael A Schwarzschild · Massachusetts General Hospital · U01 · FY2018 · NS
Programming and Reprogramming Human Cells
$852,794Rudolf Jaenisch · Whitehead Institute For Biomedical Res · R01 · FY2011 · CA
CAREER: Leaving the Fold: Leveraging Mass Spectrometry Proteomics to Shift the Paradigm on Protein Folding
$852,387Stephen D Fried · Johns Hopkins University · · FY2021 · BIO
Human Embryonic Stem Cells: Characterization and Dopaminergic Differentiation
$851,782William Freed · National Institute On Drug Abuse · ZIA · FY2013 · DA
Development of STEP Allosteric Inhibitors as Novel Therapeutics for Alzheimer's Disease
$851,505Lutz Tautz · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2022 · AG
Pharmacology And Physiology Of The Substantia Nigra And Basal Ganglia
$851,192Judith Richmon Walters · National Institute Of Neurological Disorders And Stroke · ZIA · FY2019 · NS
RNA Targeted Drug Discovery and Development for Parkinson Disease
$851,067M. Maral Mouradian · Rbhs-Robert Wood Johnson Medical School · UH3 · FY2021 · NS